会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • METHOD FOR EVALUATING THERAPEUTIC EFFICACY
    • 评估治疗效果的方法
    • WO2002064092A2
    • 2002-08-22
    • PCT/US2002/004462
    • 2002-02-15
    • KOSAN BIOSCIENCES, INC.CARRERAS, ChristopherDILLON, Susan
    • CARRERAS, ChristopherDILLON, Susan
    • A61K
    • G01N33/5041C07H21/04C07K14/723G01N33/5008G01N33/566G01N33/74G01N2333/72G01N2333/726G01N2500/00
    • The present invention relates to in vitro methods for evaluating compounds that better correlate with therapeutic efficiency than evaluating compounds based on potency alone. In general, the inventive methods comprises: (i) determining a potency value for a compound against its target receptor; (ii) determining a potency value for a compound against its target receptor; and (iii) comparing the potency value wit the desensitization value. If the desired action of a compound is as a receptor agonist, the compound's desensitization value should be larger than the compound's potency value. This ensures that the concentration of a compound required for potency will not also cause the receptor to desensitize at the same time, thus in an essence nullifying the desired effect. The inventive methods are used to evaluate novel motilide compounds as well as ABT-229 and EM-574, two motilide compounds for which clinical trials have been initiated.
    • 本发明涉及用于评价与治疗效能更好相关的化合物的体外方法,而不仅仅是基于单独的效力来评价化合物。 通常,本发明的方法包括:(i)确定化合物对其靶受体的效价值; (ii)确定化合物对其靶受体的效价值; 和(iii)比较具有脱敏值的效价值。 如果化合物的所需作用是作为受体激动剂,化合物的脱敏值应大于化合物的效价值。 这确保了效力所需的化合物的浓度不会同时导致受体脱敏,因此在本质上无效期望的效果。 本发明的方法用于评价新型的动物酰胆碱化合物以及ABT-229和EM-574,这两种化合物已经开始临床试验。